Irinotecan liposomal(Jiangsu Hengrui Medicine)

伊立替康脂质体（江苏恒瑞）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameIrinotecan liposomal(Jiangsu Hengrui Medicine)
Drug Alias NameIrinotecan liposomal盐酸伊立替康脂质体越优力HR-070803
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsPancreatic Neoplasms
Approved Indications in ChinaPancreatic Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsPancreatic NeoplasmsColorectal NeoplasmsEsophageal Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksWikipedia